DK1362590T3 - Anvendelse af cilobradin eller farmaceutisk acceptable salte deraf til behandling eller forebyggelse af hjertesvigt - Google Patents

Anvendelse af cilobradin eller farmaceutisk acceptable salte deraf til behandling eller forebyggelse af hjertesvigt

Info

Publication number
DK1362590T3
DK1362590T3 DK02016602T DK02016602T DK1362590T3 DK 1362590 T3 DK1362590 T3 DK 1362590T3 DK 02016602 T DK02016602 T DK 02016602T DK 02016602 T DK02016602 T DK 02016602T DK 1362590 T3 DK1362590 T3 DK 1362590T3
Authority
DK
Denmark
Prior art keywords
cilobradine
prevention
treatment
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
DK02016602T
Other languages
English (en)
Inventor
Brian Guth Dr
Randolf Seidler Dr
Juergen Daemmgen Dr
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29265956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1362590(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK1362590T3 publication Critical patent/DK1362590T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02016602T 2002-07-25 2002-07-25 Anvendelse af cilobradin eller farmaceutisk acceptable salte deraf til behandling eller forebyggelse af hjertesvigt DK1362590T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02016602A EP1362590B1 (en) 2002-07-25 2002-07-25 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Publications (1)

Publication Number Publication Date
DK1362590T3 true DK1362590T3 (da) 2004-03-29

Family

ID=29265956

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02016602T DK1362590T3 (da) 2002-07-25 2002-07-25 Anvendelse af cilobradin eller farmaceutisk acceptable salte deraf til behandling eller forebyggelse af hjertesvigt
DK03771064.7T DK1534296T3 (da) 2002-07-25 2003-07-21 Anvendelse af cilobradin eller de farmaceutisk acceptable salte deraf til behandling eller forebyggelse af hjertesvigt

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03771064.7T DK1534296T3 (da) 2002-07-25 2003-07-21 Anvendelse af cilobradin eller de farmaceutisk acceptable salte deraf til behandling eller forebyggelse af hjertesvigt

Country Status (29)

Country Link
US (1) US20130317008A1 (da)
EP (2) EP1362590B1 (da)
JP (3) JP2005533853A (da)
KR (1) KR20050074432A (da)
CN (1) CN100502874C (da)
AR (1) AR040690A1 (da)
AT (2) ATE257384T1 (da)
AU (1) AU2003254554B8 (da)
BR (1) BR0312852A (da)
CA (1) CA2493208C (da)
CO (1) CO5700723A2 (da)
CY (1) CY1112173T1 (da)
DE (1) DE60200160T2 (da)
DK (2) DK1362590T3 (da)
ES (2) ES2211846T3 (da)
HR (1) HRP20050075B1 (da)
MX (1) MXPA05000617A (da)
MY (1) MY128529A (da)
NZ (1) NZ538424A (da)
PE (1) PE20040706A1 (da)
PL (1) PL214716B1 (da)
PT (2) PT1362590E (da)
SA (1) SA03240350B1 (da)
SI (2) SI1362590T1 (da)
TR (1) TR200400127T4 (da)
TW (1) TWI319321B (da)
UY (1) UY27910A1 (da)
WO (1) WO2004011006A1 (da)
ZA (1) ZA200500084B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1362590B1 (en) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1917979A4 (en) * 2005-08-23 2009-06-03 Astellas Pharma Inc THERAPEUTICS FOR PREVIOUS LIVING ROOMS
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2927538B1 (fr) 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
EP3318247A1 (en) 2011-08-12 2018-05-09 Boehringer Ingelheim Vetmedica GmbH Taste masked pharmaceutical composition
EP2953612A1 (en) 2013-02-11 2015-12-16 Boehringer Ingelheim Vetmedica GmbH Kit-of-parts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) * 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
JP4240173B2 (ja) * 1998-06-03 2009-03-18 日産化学工業株式会社 インダン誘導体
DE60009287T2 (de) * 1999-06-03 2005-02-17 Yamanouchi Pharmaceutical Co., Ltd. Neuartige isoquinolin-derivate oder salze davon
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
EP1362590B1 (en) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Also Published As

Publication number Publication date
DE60200160T2 (de) 2004-11-04
TW200412974A (en) 2004-08-01
PE20040706A1 (es) 2004-12-06
EP1534296B1 (en) 2011-05-25
SI1362590T1 (en) 2004-04-30
BR0312852A (pt) 2005-04-19
PL214716B1 (pl) 2013-09-30
JP2013166781A (ja) 2013-08-29
AU2003254554A1 (en) 2004-02-16
TR200400127T4 (tr) 2004-02-23
MY128529A (en) 2007-02-28
CN1671392A (zh) 2005-09-21
ES2367109T3 (es) 2011-10-28
NZ538424A (en) 2006-10-27
MXPA05000617A (es) 2005-08-19
ZA200500084B (en) 2005-10-26
DE60200160D1 (de) 2004-02-12
SA03240350B1 (ar) 2007-10-29
HRP20050075A2 (en) 2005-12-31
SI1534296T1 (sl) 2011-09-30
KR20050074432A (ko) 2005-07-18
US20130317008A1 (en) 2013-11-28
CA2493208C (en) 2011-11-01
DK1534296T3 (da) 2011-08-15
AU2003254554B8 (en) 2009-02-26
EP1362590A8 (en) 2004-02-25
ATE510543T1 (de) 2011-06-15
TWI319321B (en) 2010-01-11
JP2005533853A (ja) 2005-11-10
UY27910A1 (es) 2004-02-27
JP2009256379A (ja) 2009-11-05
CY1112173T1 (el) 2015-12-09
PT1362590E (pt) 2004-05-31
HRP20050075B1 (hr) 2013-12-20
EP1534296A1 (en) 2005-06-01
EP1362590A1 (en) 2003-11-19
CN100502874C (zh) 2009-06-24
PT1534296E (pt) 2011-08-18
ES2211846T3 (es) 2004-07-16
CA2493208A1 (en) 2004-02-05
ATE257384T1 (de) 2004-01-15
AU2003254554B2 (en) 2009-01-29
PL372993A1 (en) 2005-08-08
AR040690A1 (es) 2005-04-13
CO5700723A2 (es) 2006-11-30
EP1362590B1 (en) 2004-01-07
WO2004011006A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
LTC1830843I2 (lt) Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
LTC1562603I2 (lt) Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
NO20044054L (no) Administrering av midler for behandling av betennelse
NO20052626D0 (no) Middel for forhindring eller behandling av neuropati
DK1446122T3 (da) Anvendelse af flibanserin til behandling af uregelmæssigheder ved könsdriften
DK1522314T3 (da) Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse
NO20054264D0 (no) Ikke-Nukleoside Revers Transkriptase-Inhibitorer I for behandling av HIV-medierte sydommer
DK2311818T3 (da) Kombination af en 5-phenylthiazolforbindelse som PI3-kinasehæmmer med et antiinflammatorisk, bronchodilatorisk eller antihistaminisk medikament
NO20034590L (no) Fremgangsmåter for behandling av vaskul¶r sykdom
DK1354597T3 (da) Farmaceutisk kombination til behandling af vævsskader forårsaget af en arterieirrigationsdefekt
DE50311735D1 (de) Das tissue engineering von knochen
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
NO20045554L (no) Fremgangsmate for behandling av diabetes
PT1154777E (pt) Medicamento para o tratamento de hipertensao arterial
DK1411917T3 (da) Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bevægelsesforstyrrelser
DK1614419T3 (da) Midler til forebyggelse/behandling af retinale nervesygdomme, indeholdende alkyletherderivater eller salte deraf
DK1362590T3 (da) Anvendelse af cilobradin eller farmaceutisk acceptable salte deraf til behandling eller forebyggelse af hjertesvigt
DK1173179T3 (da) Anvendelse af saredutant og de farmaceutisk acceptable salte heraf til behandling eller forebyggelse af svær depressiv forstyrrelse
DE60326734D1 (de) Ligations-behandlungsgerät
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
NO20040497L (no) Amidinderivater for behandling av amyloidose
ES1052302Y (es) Soporte de suministros medicos.
DK1157987T3 (da) S-nitrosothioler som midler til behandling af kredsløbsforstyrrelser
DK1446131T3 (da) Anvendelse af specifik dosis af fondaparinux-natrium til behandling af ACS